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Abstract
OBJECTIVE—We evaluated mononuclear cell (MNC) preactivation in women with Polycystic 
Ovary Syndrome (PCOS) by examining the effect of in vitro lipopolysaccharide (LPS) exposure 
on cytokine release in the fasting state.
STUDY DESIGN—Twenty women with PCOS (10 lean, 10 obese) and 20 weight-matched 
controls (10 lean, 10 obese) volunteered for study participation. Tumor necrosis factor-α (TNF α) 
and interleukin-6 (IL-6) release was measured from mononuclear cell isolated from fasting blood 
samples and cultured in the presence and absence of lipopolysaccharide. Plasma IL-6 was 
measured from the same fasting blood samples. Insulin sensitivity was derived from an oral 
glucose tolerance test using the Matsuda index and truncal fat was measured by dual energy x-ray 
absorptiometry.
RESULTS—The percent change from baseline in TNFα and IL-6 release from mononuclear cell 
following lipopolysaccharide exposure was increased (pitalic>0.04) in lean and obese women with 
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PCOS and obese controls compared with lean controls. Plasma IL-6 was increased (pbold>0.02) in 
obese women with PCOS compared with lean women with PCOS, which in turn was increased 
(p<0.02) compared with lean controls. The mononuclear cell -derived TNFα and IL-6 responses 
from mononuclear cell were negatively correlated with insulin sensitivity (p<0.03) and positively 
correlated with testosterone (p<0.03) and androstenedione (p<0.006) for the combined groups. 
Plasma IL-6 was positively correlated with percent truncal fat (p<0.008).
CONCLUSIONS—In PCOS, increased cytokine release from mononuclear cell following 
lipopolysaccharide exposure in the fasting state reveals the presence of mononuclear cell 
preactivation. Importantly, this phenomenon is independent of obesity and may contribute to the 
development of insulin resistance and hyperandrogenism in PCOS. In contrast, the source of 
plasma IL-6 elevations in PCOS may be excess adiposity.
Keywords
inflammation; lipopolysaccharide; mononuclear cell preactivation
Introduction
The Polycystic Ovary Syndrome (PCOS) affects as many as 15% of reproductive-age 
women and is characterized by hyperandrogenism, chronic oligo- or anovulation and 
polycystic ovaries.1,2 Obesity and insulin resistance are often present in PCOS and the 
compensatory hyperinsulinemia is thought to promote the hyperandrogenism.3,4 Many 
young women with PCOS also possess risk factors for cardiovascular disease such as 
metabolic syndrome, type 2 diabetes, dyslipidemia and hypertension which are associated 
with atherosclerosis.5,6 In PCOS, oxidative stress and chronic low-grade inflammation have 
been implicated in the development of insulin resistance and accelerated atherogenesis.7–9 
Women with PCOS exhibit increased circulating levels of protein carbonyls, tumor necrosis 
factor-α (TNF α) and interleukin-6 (IL-6), decreased insulin signaling and a higher 
prevalence of coronary artery calcification.10–14
Our previous studies have highlighted the ability of nutrient ingestion to trigger a prooxidant 
proinflammatory response from peripheral blood mononuclear cells (MNC) that is 
independent of obesity.8,15–19 Indeed, MNC of lean women with PCOS exhibit increases in 
reactive oxygen species (ROS) generation and nuclear factor κB (NFκB) activation 
following ingestion of glucose and lipid.17,20 NFκB regulates the transcription of a variety 
of inflammatory mediators including that of TNFα and IL-6. These cytokines exert positive 
feedback to up-regulate the preceding molecular events that mediate insulin resistance and 
atherogenesis.21,22 Thus, MNC of women with PCOS have an increased sensitivity to 
nutrient ingestion.
MNC preactivation in the fasting state may account for increased MNC sensitivity in PCOS. 
In this instance, the NFκB inflammation pathway that culminates in cytokine release from 
MNC may already be upregulated prior to nutrient ingestion similar to what has been 
reported in obesity.23 As such, we evaluated MNC obtained in the fasting state for the 
amount of TNFα and IL-6 release following in vitro exposure to lipopolysaccharide (LPS) 
and also evaluated the status of fasting plasma IL-6 in women with PCOS. We anticipated 
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that plasma IL-6 would be elevated in these women based on previous studies.14 However, 
we hypothesized that MNC-derived cytokine release is increased in response to in vitro LPS 
exposure in women with PCOS compared with weight-matched controls; and that this 
cytokine response to LPS along with plasma IL-6 levels are related to abdominal adiposity, 
insulin sensitivity and circulating androgens.
Materials and Methods
Subjects
Twenty women with PCOS (10 lean and 10 obese) 20–34 years of age and 20 weight-
matched control subjects (10 lean and 10 obese) 20–39 years of age volunteered for study 
participation. Some subjects in the current study were involved in our previous work on 
PCOS and insulin resistance.16 Additional subjects were recruited via newspaper 
advertisements and flyers within the Indiana University community between the years 2011 
and 2013. Obesity was defined as a body mass index (BMI) between 30 and 40 kg/m2. Lean 
subjects had a BMI between 18 and 25 kg/m2. The women with PCOS were diagnosed on 
the basis of oligo-amenorrhea and hyperandrogenemia after excluding nonclassic congenital 
adrenal hyperplasia, Cushing’s Syndrome, hyperprolactinemia and thyroid disease. 
Polycystic ovaries were present on ultrasound in all subjects with PCOS. All control 
subjects had regular menses lasting 25 to 35 days and a luteal range serum progesterone 
level consistent with ovulation (>5 ng/ml). All control subjects exhibited normal circulating 
androgen levels and did not have any skin manifestations of androgen excess or polycystic 
ovaries on ultrasound.
Diabetes and inflammatory illnesses were excluded in all subjects. None of them suffered 
from depression, smoked tobacco, ingested more than two alcoholic beverages per month or 
used medications that could impact carbohydrate metabolism or immune function for a 
minimum of 6 weeks before beginning the study. All subjects were sedentary defined as 
exercise less than once a month during the 6 months before study participation. Written 
informed consent was obtained from all subjects according to Institutional Review Board 
guidelines.
Study Design
All study subjects were provided with a healthy diet consisting of 50% carbohydrate, 35% 
fat and 15% protein for 3 consecutive days before testing between days 5 and 8 after the 
onset of menstruation. All but one of the subjects was compliant with the diet based on 
completion of a checklist of consumed food and inspection of returned empty food 
containers. The less compliant individual was a lean control who consumed 85% of the food 
provided. Testing began with an assessment of body composition. After an overnight fast of 
~12 hours, a blood sample was obtained for MNC isolation and culture, and to isolate 
plasma that was stored at −80° C until assayed for IL-6. All study subjects then underwent 
an oral glucose tolerance test (OGTT) to assess insulin sensitivity.
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Body Composition Assessment
Height without shoes was measured to the nearest 1.0 cm. Body weight was measured to the 
nearest 0.1 kg. Waist circumference was measured at the level of the umbilicus and used to 
estimate abdominal adiposity. In addition, all subjects underwent dual energy x-ray 
absorptiometry to determine percent total body fat and percent truncal fat using the QDR 
4500 Elite model scanner (Hologic Inc., Waltham, MA) as previously described.15,24
MNC Culture
MNC were isolated by density gradient centrifugation in Histopaque-1077 (Sigma-Aldrich 
Co., St. Louis, MO). The cells were washed twice in pyrogen-free saline, resuspended in 
RPMI (0.3mg/ml L-glutamine, 100 U/ml penicillin, 100 ug/ml streptomycin) with TCH™ 
Serum Replacement (MD Biomedicals, Inc., Irvine, CA) and seeded in coated culture plates 
(VWR International, West Chester, PA) at a concentration of 2.5×106 cells/ml. The cells 
were then incubated (95% humidity, 5% CO2, 37° C) for 24 hours in the presence (exposed) 
and absence (unexposed) of 1 ng/ml of LPS endotoxin from Escherichia coli 0127:B8 
(Sigma-Aldrich Co. LLC, St. Louis, MO). Culture supernatants were collected and stored at 
−80° C until assayed for TNFα and IL-6.
Oral Glucose Tolerance Test
Blood samples were drawn at 0, 30, 60, 90, 120 and 180 minutes after ingestion of a 75 gm 
glucose beverage to measure glucose and insulin. Plasma glucose concentrations were 
assayed immediately, and insulin measurements were performed later from plasma stored at 
−80° C. Insulin sensitivity was derived using the Matsuda index formula (ISOGTT): 10,000 
divided by the square root of (fasting glucose x fasting insulin) x (mean glucose x mean 
insulin).25 This particular formula is highly correlated with insulin sensitivity measurements 
using the gold standard hyperinsulinemic-euglycemic clamp procedure.25–27
Serum, Plasma and Culture Supernatant Measurements
Serum luteinizing hormone (LH), testosterone, androstenedione and 
dehydroepiandrosterone-sulfate (DHEA-S) levels were measured by RIA (Siemens Medical 
Solutions Diagnostics, Los Angeles, CA). Plasma glucose was measured by the glucose 
oxidase method (YSI 2300 STAT Plus, Yellow Springs, OH), while plasma insulin was 
measured by a double antibody RIA (Millipore, St. Charles, MO). Plasma IL-6 
concentrations along with those of TNFα and IL-6 in MNC culture supernatants were 
measured by ELISA (eBioscience, San Diego, CA). The interassay and intraassay 
coefficients of variation for all assays did not exceed 7.4% and 12%, respectively.
Statistics
Data were analyzed using StatView (SAS Institute, Cary, NC). All values were initially 
examined graphically for departure from normality, and the natural logarithm transformation 
was applied as needed. Descriptive data and change from baseline of variables were 
compared between groups using ANOVA for multiple group comparisons. The source of 
significance by ANOVA was identified by Tukey’s post hoc test. Furthermore, ANCOVA 
was performed to confirm significance of inflammation variables using significantly altered 
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metabolic parameters as covariates that might influence inflammation when comparing lean 
PCOS vs. lean controls or obese PCOS vs. obese controls. The treatment effect was 
determined by calculating the percent change in LPS-exposed cytokine release from the 
unexposed baseline for each subject in view of intersubject variability. Pearson linear 
regression was employed for correlation analyses using the method of least squares. Data are 
presented as mean ± SE, and results with a two-tailed α-level of 0.05 were considered 
significant.
Results
Age, Body Composition, Blood Pressure and Lipids
All four groups were similar in age and height (Table 1). Obese subjects had significantly 
(p<0.05) higher weight, body mass index (BMI), percent total body fat, percent truncal fat 
and waist circumference compared with lean subjects whether or not they had PCOS. 
However, these measures of body composition were similar when women with PCOS were 
compared with weight-matched controls.
Systolic blood pressure was similar among groups. Diastolic blood pressure was 
significantly (p<0.05) higher in obese controls compared with lean women with PCOS and 
lean controls, but mean values were in the normotensive range. The levels of total 
cholesterol, triglyceride and high and low density lipoprotein cholesterol were similar 
among groups.
Plasma Hormone Levels, Glycemic Status and Insulin Sensitivity
Women with PCOS exhibited significantly (p<0.05) higher serum levels of LH, testosterone, 
androstenedione and DHEA-S compared with control subjects regardless of weight class 
(Table 1). Women with PCOS who were lean had significantly (p<0.05) higher serum LH 
levels compared with those who were obese.
Women with PCOS and controls exhibited similar glucose levels while fasting and 2 hours 
post glucose ingestion regardless of weight status. All subjects had a normal glucose 
response during the OGTT, with fasting glucose levels <100 mg/dl and 2-hour glucose 
levels ranging between 75 and 137 mg/dl. Fasting insulin levels were significantly higher 
(p<0.05) in obese women with PCOS compared with lean women with PCOS and both 
control groups and in obese controls compared with lean controls. The ISOGTT was 
significantly higher (p<0.05) in obese subjects regardless of PCOS status compared with 
lean controls and in lean women with PCOS compared with lean controls.
MNC-Derived TNFα and IL-6 Release and Plasma IL-6
Baseline TNFα and IL-6 release from MNC in the fasting state was similar in all four 
groups (data not shown). The change from baseline in TNFα and IL-6 release from MNC 
following LPS exposure was significantly (p<0.04) greater in in both PCOS groups and 
obese controls compared with lean controls (Figure 1A–B).
Fasting plasma IL-6 was significantly (p<0.02) higher in obese subjects whether or not they 
had PCOS and lean women with PCOS compared with lean controls (Figure 2). Obese 
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women with PCOS also exhibited significantly (p<0.02) higher fasting plasma IL-6 levels 
compared with lean women with PCOS.
The MNC-derived TNFα and IL-6 responses and fasting plasma IL-6 remained significantly 
increased in lean women with PCOS when comparing the lean groups after controlling for 
insulin sensitivity (ISOGTT), and remained similar when comparing the obese groups after 
controlling for fasting insulin.
Correlations
Waist circumference was positively correlated with BMI (r= 0.76, p<0.0001), percent body 
fat (r= 0.61, p<0.0001) and percent truncal fat (r= 0.68, p<0.0001) and ISOGTT was 
negatively correlated with BMI (r= −0.49, p<0.002), waist circumference (r= −0.45, 
p<0.005) and percent truncal fat (r= −0.42, p<0.008) for the combined groups.
The change from baseline in IL-6 release from MNC following LPS exposure was positively 
correlated with that of TNFα and plasma IL-6 for the combined groups (Table 2). Fasting 
plasma IL-6 was positively correlated with BMI, waist circumference, percent body fat and 
percent truncal fat. The MNC-derived TNFα and IL-6 responses and plasma IL-6 were 
negatively correlated with ISOGTT and were positively correlated with serum levels of 
testosterone and androstenedione. There was also a positive correlation between MNC-
derived TNFα response and serum LH (r= 0.50, p<0.002).
In women with PCOS, fasting plasma IL-6 was positively correlated with the MNC-derived 
IL-6 response (r= 0.63, p<0.005), percent body fat (r= 0.53, p<0.002), percent truncal fat (r= 
0.60, p<0.008) and serum levels of testosterone (r= 0.46, p<0.05) and DHEA-S (r= 0.49, 
p<0.04). There was also a positive correlation between the MNC-derived IL-6 response and 
serum testosterone (r= 0.56, p<0.02).
Comment
Our data provide the first clear evidence that in PCOS, MNC are preactivated in the fasting 
state and that this phenomenon is independent of obesity. Moreover, a proinflammatory 
stimulus in the form of LPS increases MNC-derived cytokine release in the fasting state in 
lean women with PCOS compared with lean controls. There are also independent 
associations of cytokine release from MNC following LPS exposure with insulin sensitivity, 
LH, and androgens. Furthermore circulating IL-6 levels are directly associated with 
measures of adiposity. Thus, MNC preactivation may contribute to the development of 
insulin resistance and hyperandrogenism while excess abdominal adiposity may be a source 
of plasma IL-6 elevations in PCOS.
The MNC of lean healthy reproductive-age women do not appear to be preactivated. There 
is minimal increase in TNFα and IL-6 release from resting MNC following in vitro LPS 
exposure in lean controls. This is consistent with our previous reports of the MNC-derived 
responses of these cytokines in the fasting state following in vitro glucose exposure in lean 
healthy young women.16,28 These observations are important because the collective effects 
of TNFα and IL-6 are responsible for mediating insulin resistance and atherogenesis.21,22 
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Thus, the limited MNC-derived response to proinflammatory stimuli in lean young women 
may serve to maintain insulin sensitivity and curtail atherogenesis to optimize glucose 
disposal and preserve blood vessel integrity.
In contrast, resting MNC of women with PCOS are in a proinflammatory state. TNFα and 
IL-6 release from MNC is increased in response to in vitro LPS exposure in lean women 
with PCOS compared with lean controls. Obese individuals regardless of PCOS status also 
exhibit increases in these parameters compared with lean controls. These results mimic our 
previous findings for these cytokines in response to in vitro glucose exposure particularly in 
obese women with PCOS.16,28 These proinflammatory responses provide evidence of MNC 
preactivation as the underpinning for the increased MNC sensitivity to nutrient ingestion 
observed in vivo in women with PCOS.8,9,17,29 The inverse relationship between LPS-
stimulated cytokine release and insulin sensitivity supports the concept that MNC 
preactivation may ultimately play a part in the mechanism of insulin resistance. In the case 
of obese individuals regardless of PCOS status, the impetus for MNC preactivation may be 
cytokines such as TNFα and IL-6 that are secreted into the circulation from the expanded 
adipose tissue compartment as a result of inflammation induced by hypoxia-related cell 
death.23,30 In fact, there is a positive association between fasting plasma IL-6 and the MNC-
derived IL-6 response. Almost one-third of lean women with PCOS exhibit excess 
abdominal adiposity and this may contribute to MNC preactivation.31 However, excess 
adiposity does not completely account for our findings in this group based on our recent 
report of increased MNC sensitivity to glucose ingestion in lean women with PCOS who 
lack excess abdominal adiposity.27,32 Furthermore, we have recently shown that induction 
of hyperandrogenemia in lean healthy reproductive-age women without PCOS who lack 
inflammation can activate and sensitize MNC to glucose, but that suppression of 
hyperandrogenemia in lean women with PCOS does not reduce the inflammatory load.33,34 
Thus, it is possible that hyperandrogenism is the progenitor of nutrient-induced 
inflammation in PCOS, but is not required for maintenance of this phenomenon in the 
chronic state.
Our data suggest that in PCOS, the chronic presence of excess adiposity may be a primary 
source of elevated cytokines such as IL-6 in the circulation. Fasting plasma IL-6 levels are 
highest in obese women with PCOS compared with lean women with PCOS who in turn 
have IL-6 levels that are higher compared with lean controls. This pattern mimics the one 
observed for insulin sensitivity in our study subjects. Furthermore, measures of adiposity, 
including abdominal fat are positively associated with fasting plasma IL-6 levels. Roughly 
half of the IL-6 in the expanded adipose mass of obese individuals is produced by MNC-
derived macrophages and serves as a paracrine stimulator of adipocyte IL-6 production.35 
Insulin sensitivity is also inversely related to fasting plasma IL-6 and abdominal adiposity. 
Thus, circulating MNC and excess adipose tissue may be joint contributors to systemic 
inflammation and insulin resistance in PCOS.
In PCOS, MNC preactivation may ultimately result in hyperandrogenism. Circulating LH, 
testosterone, androstenedione and DHEA-S are all directly related to MNC-derived cytokine 
release and/or fasting plasma IL-6 levels. This is supported by our findings in previous 
studies.8,9,16,17,29,32 While the relationship with LH raises the possibility that inflammation 
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contributes to pituitary LH hypersecretion in PCOS to enhance androgen production, impact 
at the local level is well characterized. MNC-derived macrophages are present in the 
ovary.36 Exposure of cultured theca cells to prooxidants increases the mRNA content of 
CYP17, the androgen producing steroidogenic enzyme, whereas exposure to anti-oxidants 
such as resveratrol and statins decreases CYP17 mRNA content.37,38 Statins are also 
capable of inhibiting proliferation of theca cells from rat and human polycystic ovaries in 
vitro.39,40 Thus, excess ovarian androgen production in PCOS may be the consequence of an 
oxidative stress-induced local inflammatory response from preactivated MNC that migrate 
into the polycystic ovary. Interestingly, PCOS theca cells in long-term culture produce 
excess androgens in the absence of macrophages.41 Although this latter finding may 
represent a fostering effect of chronic in vitro conditions, it raises the possibility that a 
proinflammatory milieu within the polycystic ovary confers a permanent independent 
propensity for PCOS theca cell hyperandrogenism.
In conclusion, cytokine release from MNC following LPS exposure in the fasting state is 
increased in women with PCOS. This phenomenon is consistent with preactivation of 
circulating MNC and is independent of obesity. MNC preactivation in PCOS may be the 
cause of increased MNC sensitivity to proinflammatory nutrients that may ultimately 
contribute to insulin resistance and hyperandrogenism. Furthermore, excess abdominal 
adiposity may be the source of plasma IL-6 elevations in this disorder.
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FIGURE 1. Mononuclear cell cytokine release
Change from baseline (%, percent) in lipopolysaccharide (LPS)-exposed (A) tumor necrosis 
factor-α (TNFα) and (B) interleukin-6 (IL-6) release from an unexposed baseline in 
mononuclear cells isolated from fasting samples and cultured for 24 hours. * Significantly 
higher in obese controls compared with lean controls for TNFα (P<0.005) and IL-6 
(P<0.04). † Significantly higher in lean women with PCOS compared with lean controls for 
TNFα (P<0.0002) and IL-6 (P<0.008). ‡ Significantly higher in obese women with PCOS 
compared with lean controls for TNFα (P<0.0001) and IL-6 (P<0.001).
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FIGURE 2. Fasting plasma interleukin-6 levels
* Significantly higher in obese controls compared with lean controls (P<0.0005). † 
Significantly higher in lean women with PCOS compared with lean controls (P<0.02). ‡ 
Significantly higher in obese women with PCOS compared with lean controls (P<0.0001). § 
Significantly higher in obese women with PCOS compared with lean women with PCOS 
(P<0.02).
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TABLE 1
Age, body composition, endocrine and metabolic parameters of subjects
CONTROLS PCOS
Lean Obese Lean Obese
Age, yr 30±2 30±2 27±2 26±2
Height, cm 165.9±1.3 164.0±2.1 162.4±3.4 165.5±1.7
Body weight, kg 62.8±2.0 93.4±3.4a,b 61.1±1.9 96.6±3.5c,d
Body mass index, kg/m2 22.8±0.5 34.7±0.9a,b 23.3±0.7 35.2±1.0c,d
Total body fat, % 32.9±1.7 42.3±0.8a,b 30.3±1.4 44.5±1.2c,d
Truncal fat, % 30.2±1.7 41.7±0.8a,b 29.3±2.2 46.1±1.1c,d
Waist circumference, cm 74.2±1.4 100.8±2.9a,b 77.1±2.3 99.3±5.1c,d
Systolic blood pressure, mmHg 109±2 118±4 112±2 118±4
Diastolic blood pressure, mmHg 64±1 75±3a,b 65±3 72±4
Total cholesterol, mg/dl 177±12 188±20 177±12 178±12
Triglycerides, mg/dl 63±18 113±35 122±34 94±14
HDL – cholesterol, mg/dl 54±5 48±4 52±5 47±4
LDL – cholesterol, mg/dl 115±13 115±18 108±10 118±11
LH, mIU/ml 4.9±0.4 2.8±0.4b,f 10.7±1.2e 8.3±1.1c,d
Testosterone, ng/dl 44.5±3.3 31.4±3.9b,f 66.1±6.5e 72.6±4.7c
Androstendione, ng/ml 1.4±0.1 1.8±0.1b,f 3.3±0.3e 3.5±0.2c
DHEA-S, μg/dl 118±13 161±26b,f 343±41e 291±46c
Fasting glucose, mg/dl 87±2 87±4 84±2 88±2
2 hour glucose, mg/dl 113±6 117±5 106±8 110±6
Fasting insulin, μiU/ml 5.4±0.9 13.9±1.7a,f 11.4±1.3 19.7±3.1c,d
ISOGTT 9.4±1.0 4.6±0.9a 4.3±0.4e 3.0±0.5c
Values are expressed as means ± SE. Conversion factors to SI units: Testosterone x3.467 (nmol/liter), Androstenedione x3.492 (nmol/liter), 
DHEA-S x0.002714 (μmol/liter), Glucose x0.0551 (mmol/liter), Insulin x7.175 (pmol/liter). ISOGTT, Insulin sensitivity derived from the OGTT.
aObese Control vs. Lean Control, P < 0.03
bObese Control vs. Lean PCOS, P < 0.0007
cObese PCOS vs. Lean Control, P < 0.001
dObese PCOS vs. Lean PCOS, P < 0.05
e
Lean PCOS vs. Lean Control, P < 0.05
fObese Control vs. Obese PCOS, P < 0.05
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TABLE 2
Pearson correlations of cytokine release following LPS exposure or plasma IL-6 with body composition, 
insulin sensitivity, circulating androgens and each other for the combined groups
MNC-derived TNFα Release 
(% change)
MNC-derived IL-6 
Release (% change)
Fasting plasma IL-6 
(pg/ml)
BMI (kg/m2)
r 0.269 0.222 0.527
P 0.094 0.180 0.0007*
Waist circum (cm)
r 0.198 0.334 0.476
P 0.235 0.044* 0.003*
Total body fat (%)
r 0.142 0.170 0.453
P 0.381 0.308 0.004*
Truncal fat (%)
r 0.240 0.185 0.559
P 0.135 0.266 0.0003*
ISOGTT
r −0.606 −0.372 −0.542
P 0.0001* 0.021* 0.0004*
Testosterone (ng/dl)
r 0.348 0.522 0.322
P 0.028* 0.0008* 0.049*
Androstenedione (ng/ml)
r 0.567 0.450 0.371
P 0.0001* 0.005* 0.022*
DHEA-S (μg/dl)
r 0.261 0.192 0.006
P 0.103 0.249 0.970
LPS-stimulated TNFα Release (% change)
r ---------- 0.385 0.498
P ---------- 0.017* 0.002
LPS-stimulated IL-6 Release (% change)
r ---------- ---------- 0.694
P ---------- ---------- 0.0001*
LPS, lipopolysaccharide; TNFα, Tumor necrosis factor-α; IL-6, Interleukin-6; ISOGTT, Insulin sensitivity derived from Matsuda Index; r, 
Correlation coefficient; P, Level of significance;
*
P<0.05.
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